11月2日,三生制药(01530.HK)公告,于2026年11月2日向香港联交所提交截至2026年10月31日止月份的证券变动月报表。
2026年10月8日至14日期间,公司经2026年6月25日股东大会批准,分五次回购股份并持作库存股份,价格介于每股14.4港元至15.59港元,合计回购633.75万股。同期,公司购股权计划项下期权被行使,涉及新股66万股,行使价为每股7.62港元,所得资金总额为502.92万港元。
截至2026年10月底,公司已发行股份(不包括库存股份)为25.14亿股,库存股份为2511.35万股,已发行股份总数为25.39亿股。公司确认已符合适用的公众持股量最低要求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.